Vivos Therapeutics, Inc. reports material agreement in SEC 8-K

Vivos Therapeutics, Inc. filed an 8-K covering a material definitive agreement, an acquisition or disposition of assets, an unregistered sale of equity securities, and SEC Item 3.03. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.